Episode Details

Chemotherapy didn’t start in a clinic — it started in a war.

In this episode of Outsmart Cancer, Dr. Dino Prato, founder of Envita Medical Centers, pulls back the curtain on the origins of modern oncology and why, 80 years later, the system still relies on the same high-dose, population-based model born from wartime poisons.

From the discovery of mustard gas toxicity in 1942 to today’s billion-dollar chemotherapy industry, Dr. Prato exposes how the “sick care cartel” — pharmaceutical companies, PBMs, and hospital systems — profits from managing cancer rather than curing it. But there’s a new model rising: immune-centric precision oncology.

Dr. Prato explains how deep multi-omics mapping (DNA, RNA, immune, and spatial biology) replaces guesswork with custom-built, low-toxicity treatments that awaken the body’s immune system — turning “maximum tolerated dose” into minimum effective precision.

🎯 What You’ll Learn in This Episode:
• The wartime origins of chemotherapy and why that model still drives care today
• Why most new cancer drugs only extend life by months on average
• How PBMs and hospital markups distort care and inflate costs
• The difference between cytostatic and cytotoxic treatments — and why it matters
• How microdosed, immune-centric precision care rebuilds the body instead of breaking it
• Why DNA/RNA testing and spatial biology are the key to custom-built therapy

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak to a care coordinator: 866-830-4576

“The war on cancer was never meant to end — until precision changed the rules.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493